Why more research is needed into Alzheimer’s treatments

Share article:

Facebook
WhatsApp
Twitter
LinkedIn
Why more research is needed into Alzheimer’s treatments

For people living with Alzheimer’s and their loved ones, progress in treatment offers something precious: hope. But hopeful headlines should not obscure the work still ahead.

New medicines can slow decline in some people with early Alzheimer’s, yet they are not a cure. Research must now turn these important first steps into safer, more effective treatments that reach more people.

New Treatments for Alzheimer’s

For years, Alzheimer’s medicines have focused on relieving symptoms rather than changing the underlying disease. New treatments, based on antibodies, offer a different approach by targeting amyloid, a protein that builds up in the brain. These anti-amyloid monoclonal antibodies are thought to slow clinical cognitive and functional decline by roughly 27% to 40% in early-stage Alzheimer’s1. However, slowing deterioration is not the same as stopping it or restoring abilities already lost.

Risks of Current Dementia Treatments

Any treatment needs to offer benefits that matter in everyday life; however, safety matters just as much. Amyloid-targeting medicines can cause brain swelling in up to 24% of patients2, making careful assessment and monitoring essential. Longer follow-up is needed to understand their lasting benefits and risks. This research should help identify who is most likely to benefit, who faces greater risks, and how treatment can become safer.

A Tailored Approach

Alzheimer’s is complex andamyloid is only part of the picture; researchers are also investigating other proteins involved in the disease, and approaches that combine different treatments. The National Institute on Ageing notes that no single intervention is likely to work for everyone3. Supporting multiple research pathways gives us a better chance of developing treatments tailored to individual needs rather than expecting one medicine to solve everything.

Research Must Reflect Real Lives

Clinical trials also need to include more diverse participants and examine treatment at different disease stages. Without that evidence, important questions remain about how well results apply to the wider population. Earlier identification may help researchers test interventions sooner, while simpler diagnostic tools could reduce barriers to participation.

Participating in a Clinical Trial for Alzheimer’s Research

64% of people would consider taking part in dementia clinical research, but only 1% do4. There is currently no cure for Alzheimer’s and available medicines are limited – more treatments are needed urgently.

MAC is conducting a new study for a potential Alzheimer’s treatment, but we need your help. If you are interested in taking part in a clinical trial investigating a potential new treatment for Alzheimer’s, you can register your interest in any future MAC clinical trials via our website.

If eligible, you will receive reasonable travel expenses and a free full health check-up.

1 Journal of the Chinese Medical Association – A 2025 update on treatment strategies for the Alzheimer’s disease spectrum

2 Neurotherapeutics – Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer’s disease: Strategies and research directions

3 National Institute on Ageing – 2025 NIH Alzheimer’s Disease and Related Dementias Research Progress Report: Advances and Achievements

4 Alzheimer’s Research UK – Dementia Statistics Hub

Share article:

Facebook
WhatsApp
Twitter
LinkedIn